2022 American Transplant Congress
Tacrolimus Induces Dedifferentiation of Pancreatic Beta Cells by Inhibition of Calcineurin/NFATc2 and Islet Cell Differentiation Genes
*Purpose: Tacrolimus (FK506) is a potent immunosuppressant widely used for solid organ transplantation to prevent lymphokine gene expression by inhibiting calcineurin (CN) and its downstream…2022 American Transplant Congress
Long-Term Low-Dose Corticosteroid Therapy Can Suppress Calcineurin Inhibitor Induced Nephrotoxicity without Steroid-Related Complication in Living Kidney Transplant Recipient
Sapporo City General Hospital, Sapporo, Japan
*Purpose: The induction of calcineurin inhibitors (CNI) greatly reduced the rate of allograft rejection, although their chronic use resulted in vascular inflammation in kidney transplant…2022 American Transplant Congress
Post Transplant Virologic Outcomes in DCD Kidney Transplant Recipients Treated with Thymoglobulin Induction Immunosuppression and Maintenance Belatacept vs Calcineurin Inhibitor Therapy
*Purpose: Belatacept is an inhibitor of the T-Cell costimulatory pathway that can be used in recipients of Donation after Circulatory Death (DCD) where the intended…2022 American Transplant Congress
Pediatric Liver Transplant Factors That Influence Tacrolimus Absorption
1Children's Hospital Colorado, Aurora, CO, 2University of Colorado, Aurora, CO
*Purpose: The aim of this study was to investigate the association between various pediatric recipient characteristics at time of liver transplant and FK506 absorption 6…2022 American Transplant Congress
Impact of Biliary Reconstruction on Tacrolimus Absorption in Pediatric Liver Transplant
1Children's Hospital Colorado, Aurora, CO, 2University of Colorado, Aurora, CO
*Purpose: Tacrolimus (FK506) oral bioavailability in pediatric liver transplant recipients (LTR) is poor. Enteral FK506 is primarily absorbed in the small intestine and subject to…2022 American Transplant Congress
Post-Kidney Transplant Dementia Risk by Modifiable Risk Factors and CNIs Among Older Recipients
*Purpose: Up to 17% of older recipients develop dementia after kidney transplant (KT). While there are known modifiable risk factors for dementia among community-dwelling older…2022 American Transplant Congress
Evaluation of Different Initial Tacrolimus Dosing Regimens in Pediatric Post-Liver Transplantation
*Purpose: Tacrolimus is an immunosuppressant used in post-liver transplantation, has wide pharmacokinetic variability, particularly in pediatric patients. Therefore, this study aimed to evaluate different weight-based…2022 American Transplant Congress
Long-Term Outcomes After Conversion to a Belatacept-Based Immunosuppression in Kidney Transplant: A Matched Cohort Study
Paris Transplant Group, INSERM, Paris, France
*Purpose: Conversion to belatacept after transplant seems to be safe. However, no studies have reported the long-term efficacy and safety outcomes after conversion to belatacept…2022 American Transplant Congress
Predicted Performance of Bayesian-Based Precision Dosing Software for Tacrolimus
*Purpose: Bayesian-based precision dosing software (BPDS) has been utilized for therapeutic drug monitoring to optimize medication use. However, BPDS for tacrolimus (TAC) is not routinely…2022 American Transplant Congress
Conversion to Everolimus-Based Immunosuppression Regimen with Calcineurin Inhibitor Reduction Ameliorates Histological Damage in Kidney Transplant Recipients with Calcineurin Inhibitor-Induced Nephrotoxicity
Hokkaido University Hospital, Sapporo, Japan
*Purpose: In the last two decades, the short-term results for kidney transplantation (KTX) have improved owing to the use of calcineurin inhibitors (CNIs). However, long-term…
- 1
- 2
- 3
- …
- 16
- Next Page »